Professor Sarah Danson

BMedSci, BMBS, MSc, PhD, FRCP

School of Medicine and Population Health

School Director of Research

Professor of Medical Oncology

Professor Sarah Danson
Professor Sarah Danson
Profile picture of Professor Sarah Danson
s.danson@sheffield.ac.uk
+44 114 226 5704

Full contact details

Professor Sarah Danson
School of Medicine and Population Health
Room 227, Broomcross Building
Weston Park Hospital
Whitham Road
Sheffield
S10 2SJ
Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I am a Professor of Medical Oncology at the University of Sheffield and Honorary Consultant in Medical Oncology at Weston Park Hospital, Sheffield.

I qualified in 1996 from the University of Nottingham and was a Specialist Registrar and Cancer Research UK Clinical Research Fellow in Pharmacology at the Christie Hospital, Manchester before moving to Sheffield in November 2006.

Research interests

My clinical and research interests are in the treatment of melanoma and lung cancer, and in the early clinical assessment of new anticancer agents. Sheffield delivers early phase oncology studies and its aims are to expand the early clinical trial portfolio and produce associated translational work. I am the NIHR National Speciality Lead for Cancer: Early Phase Trials and past Chair of the national ECMC Strategy Group. I am the principal investigator on many early-phase trials. I am the Lead for the YCR CONNECTS fellowship programme.

Melanoma is on the increase and this is not all due to excess sun exposure. We enrol patients into clinical trials for melanoma if possible. I am past Chair of the Sheffield Melanoma Research Group, and past Chair of the Rare Tumour Group, which aims to increase trial activity in less common cancers such as melanoma. I am the Chief Investigator for the NIHR- funded Phase III DANTE trial looking at the optimal duration of immunotherapy in advanced melanoma. Previous studies include agents targeting VEGF (AVAST-M published in Lancet Oncology and Annals of Oncology) and MEK inhibitors (PACMEL, DOCMEK and COLUMBUS). 

I am supervising a CSC fellowship on ex vivo techniques in melanoma. I was the supervisor for a YCR Senior fellow investigating the long-term support needs of patients on immunotherapy and work in this area is ongoing. I co-supervised a CR-UK/YCR fellowship looking at JAK2 in haematological malignancies and cutaneous melanoma.  A Weston Park Cancer Charity fellow researched ctDNA taken longitudinally and correlated with epidemiological and biological features in melanoma.

Sheffield is one of three large centres for the treatment of uveal melanoma in the UK. We were top recruiters for the SUAVE study of dacarbazine versus sunitinib in metastatic uveal melanoma and the SELPAC trial in the same disease group using the MEK inhibitor selumetinib which has activity in this tumour type.

Thoracic malignancies cause major morbidity and mortality throughout the world. We undertook a collaborative study with a PhD student between the Department of Oncology and the Department of Psychology to look at the role of smoking status in attitudes to disease and treatment and Quality of Life. This was funded by WPH General Trust Funds and enrolled 296 patients with lung cancer over 3 years. I have supervised a CASE studentship in collaboration with AstraZeneca and Sheffield Children's Hospital looking at next-generation sequencing in lung cancer.  I have also supervised PhD studentships on chK1 in small cell lung cancer and AURKA expression and radiosensitivity in NSCLC.  I am the EORTC Co-ordinator on the international SPLENDOUR study of denosumab in non-small cell lung cancer.

Other current research interests include:

  • ex vivo-led therapy
  • virotherapy as a treatment for cancers
  • adrenomedullin 2 receptor targeting in cancers
Publications

Show: Featured publications All publications

Journal articles

  • Silva S & Danson S (2013) . Thoracic Surgical Clinics, 23, 411-419.
  • Marques CMG, Dibden C, Danson S, Haycock JW & MacNeil S (2013) . Journal of Cosmetics, Dermatological Sciences and Applications, 3, 175-189.
  • O'Brien ME, Gafaar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A , Hasan B et al (2013) . European Journal of Cancer.
  • Walkington LA, Lorigan P & Danson SJ (2013) . BMJ, 346, f1265.
  • Shankland K, Kirkbride P, Price J, Walkington L & Danson SJ (2012) . Journal of Comorbidity, 2(1), 10-17.
  • Rowland C, Eiser C, Rowe R & Danson S (2012) . BMJ Supportive and Pallative Care(2), 312-318.
  • Thompson R, Meuth M, Woll P, Zhu Y & Danson S (2012) . Int J Oncol, 40(1), 194-202.
  • Danson SJ, Quinn AM, Blackhall F, Wilson G, Clamp A, Ashcroft L, Brierley J & Hasleton P (2011) Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.. Histopathology, 61(3)(September 2012), 454-464.
  • Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J , Robson L et al (2011) . Ann Oncol, 22(7), 1653-1660.

All publications

Journal articles

  • Shearsmith L, Danson S, Gelcich S, Gibson A, Gordon K, Collinson F, Croft J, Griffiths E, Rogers Z, Carter R , Brown J et al (2025) . Clin Trials, 17407745251378668.
  • Gimeno-Valiente F, Castignani C, Larose Cadieux E, Mensah NE, Liu X, Chen K, Chervova O, Karasaki T, Weeden CE, Richard C , Lai S et al (2025) . Nature Genetics, 57(9), 2226-2237.
  • Danson S, Sirois F, Fradley K, Wadsley J, Ray J, Bishop R, Horsman J, Mann C, Chantry-Groves L, Young M & Bentall R (2025) . Heliyon, 11(13), e43296-e43296.
  • Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D , Ottensmeier C et al (2025) . Nature Communications, 16(1).
  • Dijkstra KK, Vendramin R, Karagianni D, Witsen M, Gálvez-Cancino F, Hill MS, Foster KA, Barbè V, Angelova M, Hynds RE , Pearce DR et al (2025) . Cancer Cell.
  • Fradley K, Sirois F, Bentall R, Ray J, Bishop R, Wadsley J & Danson S (2025) . British Journal of Health Psychology, 30(3).
  • Ahmed A, Cox E, Lane L, Rominiyi O, Danson S, Bryant HE, Wells G & King D (2025) . Journal of Pediatric Hematology/Oncology, 47(5), e144-e154.
  • Bentham R, Jones TP, Black JRM, Martinez-Ruiz C, Dietzen M, Litovchenko M, Thol K, Watkins TBK, Bailey C, Pich O , Zhang Z et al (2025) . Nature Genetics, 57, 694-705.
  • Black JRM, Bartha G, Abbott CW, Boyle SM, Karasaki T, Li B, Chen R, Harris J, Veeriah S, Colopi M , Bakir MA et al (2025) . Nature Medicine, 31(1), 70-76.
  • Biswas D, Liu Y-H, Herrero J, Wu Y, Moore DA, Karasaki T, Grigoriadis K, Lu W-T, Veeriah S, Naceur-Lombardelli C , Magno N et al (2025) . Nature Cancer, 6, 86-101.
  • Zhao A, Maple L, Jiang J, Myers KN, Jones CG, Gagg H, McGarrity-Cottrell C, Rominiyi O, Collis SJ, Wells G , Rahman M et al (2024) . Cell Death & Disease, 15(12).
  • Lobon I, Shum B, Egan D, Fidan R, Lesluyes T, Jiang Q, Pallikonda H, Khoja L, Nahm SH, El Badri S , Peleva E et al (2024) . Immuno-Oncology and Technology, 24, 100897-100897.
  • Puttick C, Jones TP, Leung MM, Galvez-Cancino F, Liu J, Varas-Godoy M, Rowan A, Pich O, Martinez-Ruiz C, Bentham R , Dijkstra KK et al (2024) . Nature Genetics, 56, 2121-2131.
  • Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A , Hill MS et al (2024) . Nature, 631(8022), E15-E15.
  • Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, Watkins TBK, Markovets A, Dry JR, Brown AP , van der Aart J et al (2024) . Nature Communications, 15.
  • Hynds RE, Huebner A, Pearce DR, Hill MS, Akarca AU, Moore DA, Ward S, Gowers KHC, Karasaki T, Al Bakir M , Wilson GA et al (2024) . Nature Communications, 15(1).
  • Rahman MM, Wells G, Rantala JK, Helleday T, Muthana M & Danson SJ (2024) . Expert Review of Clinical Immunology, 20(8), 821-838.
  • Sacco JJ, Jackson R, Corrie P, Danson S, Evans TRJ, Ochsenreither S, Kumar S, Goodman A, Larkin J, Karydis I , Steven N et al (2024) . European Journal of Cancer, 202.
  • Pan X, AbdulJabbar K, Coelho-Lima J, Grapa A-I, Zhang H, Cheung AHK, Baena J, Karasaki T, Wilson CR, Sereno M , Veeriah S et al (2024) . Nature Cancer, 5(2), 347-363.
  • Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B , Carser J et al (2024) . European Journal of Cancer, 196.
  • Hapuarachi B, Danson S, Wadsley J & Muthana M (2023) . Frontiers in Immunology, 14.
  • Jones RP, Lee LYW, Corrie PG, Danson S & Vimalachandran D (2023) . British Journal of Surgery, 110(12), 1883-1884.
  • Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al (2023) . F1000Research, 12.
  • Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, Veeriah S, Moreau M, Chesh A, Chaunzwa TL , Weiss J et al (2023) . Nature, 616(7957), 553-562.
  • Al Bakir M, Huebner A, Martínez-Ruiz C, Grigoriadis K, Watkins TBK, Pich O, Moore DA, Veeriah S, Ward S, Laycock J , Johnson D et al (2023) . Nature, 616, 534-542.
  • Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A , Hill MS et al (2023) . Nature, 616, 525-533.
  • Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C , Toncheva A et al (2023) . Nature, 616, 543-552.
  • Karasaki T, Moore DA, Veeriah S, Naceur-Lombardelli C, Toncheva A, Magno N, Ward S, Bakir MA, Watkins TBK, Grigoriadis K , Huebner A et al (2023) . Nature Medicine, 29(4), 833-845.
  • Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, Kidd AC, Frankell AM, Watkins TBK, Martínez-Ruiz C , Puttick C et al (2023) . Nature Medicine, 29(4), 846-858.
  • Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, Karasaki T, Moore DA, Salgado R, Sivakumar M , Young G et al (2023) . Nature, 616, 563-573.
  • Hill W, Lim EL, Weeden CE, Lee C, Augustine M, Chen K, Kuan F-C, Marongiu F, Evans EJ, Moore DA , Rodrigues FS et al (2023) . Nature, 616(7955), 159-167.
  • Danson S, Sirois F, Fradley K, Wadsley J, Ray J, Bishop R, Horsman J, Mann C, Chantry-Groves L, Young M & Bentall R (2023) . Heliyon, 9(3).
  • Peters S, Letovanec I, Mauer M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth A, Pokharel S, Reinmuth N , Majem Tarruella M et al (2023) . Lung Cancer, 175, 141-151.
  • Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al (2022) . Future Pharmacology, 2(4), 444-459.
  • Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) . Expert Reviews in Molecular Medicine, 24.
  • Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G & Casbard A (2022) . eClinicalMedicine, 52.
  • Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, Shah R, Bhosle J, Hodgkinson E, Watkins B & Billingham L (2022) . Lung Cancer, 171, 26-33.
  • Howard F, Conner J, Danson S & Muthana M (2022) . Frontiers in Molecular Biosciences, 9.
  • Lee RW, Danson S, Elliot M, Park EI, Pinkney TD, Shaw CE, Vimalachandran D, Maughan T, Seymour M, Corrie P & Wadsley J (2022) . The Lancet Oncology, 23(8), 975-978.
  • Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Morton C, Joseph M , Hessey S et al (2022) . Nature Cancer, 3, 696-709.
  • Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L , Gardner G et al (2022) . eClinicalMedicine, 48.
  • Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P & Nye M (2022) . The Lancet Oncology, 23(1), e14-e15.
  • Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L , Lord J et al (2021) . The Lancet Oncology, 22(11), 1530-1540.
  • Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA , Jamal-Hanjani M et al (2021) . Nature, 597(7877), 555-560.
  • Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe H-S, Bustin F, Crequit J, Coate L, Guillot M , Surmont V et al (2021) . Lung Cancer, 161, 76-85.
  • Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J , Velikova G et al (2021) . BMC Cancer, 21(1).
  • Kennedy F, Shearsmith L, Ayres M, Lindner OC, Marston L, Pass A, Danson S & Velikova G (2021) . Clinical Trials, 18(2), 168-179.
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2021) . Clinical Cancer Research, 27(7), 1882-1892.
  • Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al (2020) . Mol Cancer Ther.
  • Merry E, Marples M, Danson S, Harding D, Denny J, Vazquez I, Chesshire L, Taylor F, Fusi A & Dalgleish A (2020) . Molecular and Clinical Oncology, 13(6), 1-4.
  • Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M , Rodriguez-Abreu D et al (2020) . Journal of Thoracic Oncology, 15(10), 1647-1656.
  • Gomes F, Lewis A, Morris R, Parks R, Kalsi T, Babic-Illamn G, Baxter M, Colquhoun K, Rodgers L, Smith E , Greystoke A et al (2020) . ecancermedicalscience, 14.
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot DC, Child J, Farrelly L, Sharkey AJ, Busacca S, Ngai Y , Hackshaw A et al (2020) . Clinical Cancer Research, 26(18), 4748-4755.
  • Wyld L, Bellantuono I, Tchkonia T, Morgan J, Turner O, Foss F, George J, Danson S & Kirkland JL (2020) . Cancers, 12(8).
  • Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T , Ronel T et al (2020) . Nature Medicine, 26(7), 1148-1148.
  • Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L , Greco M et al (2020) . Nature Medicine, 26(7), 1148-1148.
  • Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N , Pierce J et al (2020) . Nature Medicine, 26(7), 1147-1147.
  • AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M , Zapata L et al (2020) . Nature Medicine, 26(7), 1054-1062.
  • López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK, Rowan A, Dewhurst SM , Birkbak NJ et al (2020) . Nature Genetics, 52(3), 283-293.
  • Danson S, Mulvey MR, Turner L, Horsman J, Escott KJ, Coleman RE, Ahmedzai SH, Bennett MI & Andrew D (2019) . Journal of Bone Oncology, 19.
  • Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S & Corrie P (2019) . British Journal of Cancer, 121(8), 629-630.
  • Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ , Marshall E et al (2019) . Annals of Oncology, 30(12), 2013-2014.
  • Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S , Griffiths R et al (2019) . OncoImmunology, 8(6).
  • Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K , Henry JY et al (2019) . Nature, 567(7749), 479-485.
  • Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C , Goff M et al (2019) . Annals of Oncology, 30(2), 317-324.
  • Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V , Barlesi F et al (2018) . Lung Cancer, 124, 298-309.
  • Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V , Barlesi F et al (2018) . Lung Cancer, 124, 310-316.
  • Silva S, Danson S, Teare MD, Taylor F, Bradford J, McDonagh A, Salawu A, Wells G, Burghel G, Brock I , Connley D et al (2018) . Clinical Chemistry, 64(9), 1338-1346.
  • Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ , Marshall E et al (2018) . Annals of Oncology, 29(8), 1843-1852.
  • Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J , Ottensmeier C et al (2018) . Trials, 19(1).
  • Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C , Henry JY et al (2018) . Cancer Cell, 33(4), 649-663.e4.
  • Crabb S, Danson SJ, Catto JWF, McDowell C, Lowder JN, Caddy J, Dunkley D, Rajaram J, Ellis D, Hill S , Hathorn D et al (2018) . Trials, 19.
  • Hardy-Werbin M, Arpi O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A , Albanell J et al (2018) . OncoImmunology, 7(2).
  • McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J , Swanton C et al (2017) . Cell, 171(6), 1259-1271.e11.
  • Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Quesne JL, Moore DA, Veeriah S, Rosenthal R , Marafioti T et al (2017) . Nature, 545, 446-451.
  • Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A , Ben Aissa A et al (2017) . Immunity, 46(4), 577-586.
  • Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C , Potter V et al (2016) . Journal of Thoracic Oncology, 11(9), 1511-1521.
  • Rowland C, Danson SJ, Rowe R, Merrick H, Woll PJ, Hatton MQ, Wadsley J, Ellis S, Crabtree C, Horsman JM & Eiser C (2016) . BMJ Support Palliat Care, 6(1), 35-42.
  • Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M , Tulasi V et al (2015) . Journal of Medicinal Chemistry, 58(23), 9309-9333.
  • Danson S (2015) . British Journal of Healthcare Management, 21(11), 506-508.
  • Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K , Rao A et al (2015) . Melanoma Research, 25(5), 432-442.
  • Danson SJ, Rowland C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton MQ, Woll PJ & Eiser C (2015) . Supportive Care in Cancer.
  • Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M , Gonzalez-Angulo AM et al (2015) . Cancer Research, 75(17), 3479-3491.
  • Thomas SJ, Snowden JA, Zeidler MP & Danson SJ (2015) . British Journal of Cancer, 113(3), 365-371.
  • Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S & Zeidler MP (2015) . PLoS ONE, 10(7).
  • Hammond DW, Al-Shammari NSD, Danson S, Jacques R, Rennie IG & Sisley K (2015) . Investigative Opthalmology & Visual Science, 56(6), 3460-3466.
  • Thomas S, Fisher K, Snowden J, Danson S, Brown S & Zeidler M (2015) . The Lancet, 385, S98-S98.
  • Bird J, Coleman P & Danson S (2015) . Journal of Clinical Nursing, 24(7-8), 937-947.
  • Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S , Gadgeel SM et al (2014) . Journal of Thoracic Oncology, 9(11), 1704-1708.
  • Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M , Danson SJ et al (2014) . Lancet Oncol, 15(6), 620-630.
  • Khan F, Ottensmeier C, Szabo M, Bates AT, Popat S, Dua D, Dorey N, Ellis S, Upadhyay S, Califano R , Lee L et al (2014) . European Journal of Cancer.
  • Silva S & Danson S (2013) . Thoracic Surgical Clinics, 23, 411-419.
  • Marques CMG, Dibden C, Danson S, Haycock JW & MacNeil S (2013) . Journal of Cosmetics, Dermatological Sciences and Applications, 3, 175-189.
  • O'Brien ME, Gafaar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A , Hasan B et al (2013) . European Journal of Cancer.
  • Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan PD et al (2013) . Journal of Clinical Oncology, 31(15_suppl), 9068-9068.
  • Talbot DC, Blackhall FH, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmuller CA, Pinder MC, Mezger J, Danson S , Callies S et al (2013) . Journal of Clinical Oncology, 31(15_suppl), 8051-8051.
  • Ahmad S, Qian W, Ellis SG, Khattak MA, Gupta A, Thillai K, Board RE, Nobes J, Dalgleish A, Grumett SA , Maraveyas A et al (2013) . Journal of Clinical Oncology, 31(15_suppl), 3018-3018.
  • Walkington LA, Lorigan P & Danson SJ (2013) . BMJ, 346, f1265.
  • Shankland K, Kirkbride P, Price J, Walkington L & Danson SJ (2012) . Journal of Comorbidity, 2(1), 10-17.
  • Rowland C, Eiser C, Rowe R & Danson S (2012) . BMJ Supportive and Pallative Care(2), 312-318.
  • Thompson R, Meuth M, Woll P, Zhu Y & Danson S (2012) . Int J Oncol, 40(1), 194-202.
  • Danson SJ, Quinn AM, Blackhall F, Wilson G, Clamp A, Ashcroft L, Brierley J & Hasleton P (2011) Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.. Histopathology, 61(3)(September 2012), 454-464.
  • Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP & Middleton MR (2011) . Melanoma Res, 21(6), 502-508.
  • Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J , Robson L et al (2011) . Ann Oncol, 22(7), 1653-1660.
  • O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Gonzalez R, Trefzer U, Mohr P , Ottensmeier et al (2011) A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. British Journal of Cancer(105), 346-352.
  • O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Gonzalez R, Trefzer U & Mohr P (2011) . British Journal of Cancer(105), 346-352.
  • Wheatley-Price P, Blackhall F, Lee S-M, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R , Danson S et al (2010) . Ann Oncol, 21(10), 2023-2028.
  • Wilson C & Danson SJ (2010) . Lung Cancer: Targets and Therapy, 1, 37-51.
  • Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R , Morris C et al (2010) . Ann Oncol, 21(4), 884-894.
  • Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J , Dickinson G et al (2009) . J Clin Oncol, 27(10), 1660-1666.
  • Danson S, Dean E, Dive C & Ranson M (2007) . Curr Cancer Drug Targets, 7(8), 785-794.
  • O'Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D & Ranson M (2007) . J Clin Oncol, 25(22), 3266-3273.
  • Danson S, Johnson P, Ward T, Dawson M, Denneny O, Watson A, Jowle D, Sharpe P, Dive C & Ranson M (2007) . Journal of Clinical Oncology, 25(18_suppl), 2514-2514.
  • Lakshminarayana P, Danson S, Suvarna K & Hancock B (2007) . J Med Case Rep, 1, 21.
  • Danson S, Ranson M, Denneny O, Cummings J & Ward TH (2007) . Cancer Chemother Pharmacol, 60(6), 851-861.
  • Danson SJ, Lakshmiarayana P, Survana K & Hancock B (2007) Atrial and placental melanoma metastasis: a case report and literature review, 1, 21-25.
  • Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L & Talbot D (2006) . Journal of Thoracic Oncology, 1(9), 984-990.
  • Payne M, Ellis P, Dunlop D, Ranson M, Danson S, Schacter L & Talbot D (2006) DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial.. J Thorac Oncol, 1(9), 984-990.
  • Danson S & Lorigan P (2006) . Ann Oncol, 17(4), 539-541.
  • Welman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD & Dive C (2006) . Neoplasia, 8(11), 905-916.
  • Danson S, Blackhall F, Hulse P & Ranson M (2005) . Drug Saf, 28(2), 103-113.
  • Danson S & Lorigan P (2005) . Drugs, 65(6), 733-743.
  • Baka S, Ranson M, Lorigan P, Danson S, Linton K, Hoogendam I, Mettinger K & Thatcher N (2005) . Eur J Cancer, 41(11), 1547-1550.
  • Blackhall F, Papakotoulas PI, Danson S & Thatcher N (2005) . Expert Opin Pharmacother, 6(7), 1157-1167.
  • Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RHJ & Butler J (2005) . Clin Cancer Res, 11(7), 2695-2701.
  • Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N , Manegold C et al (2005) . LUNG CANCER-J IASLC, 47(1), 69-80.
  • Clamp A, Danson S, Nguyen H, Cole D & Clemons M (2004) . Lancet Oncol, 5(10), 607-616.
  • Clayton AJ, Danson S, Jolly S, Ryder WDJ, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G , Howell A et al (2004) . Br J Cancer, 91(4), 639-643.
  • O'Byrne K, Clarke L, Dunlop D, Ranson M, Danson S, Botwood N & Carbone D (2004) . Journal of Clinical Oncology, 22(14_suppl), 7101-7101.
  • Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G & Ranson M (2004) . Br J Cancer, 90(11), 2085-2091.
  • Danson S (2004) . Cancer Treat Rev, 30(3), 309-314.
  • Danson S, Ward TH, Butler J & Ranson M (2004) . Cancer Treat Rev, 30(5), 437-449.
  • Le Chevalier T, Brown A, Fitzgerald P, Aristides M, Natale R, Scagliotti G, Vansteenkiste J, Van Meerbeeck JL, Rosell R, Rudd RM , Danson S et al (2003) A meta-analysis of platinum-based GEMZAR® in non-small cell lung cancer (NSCLC). Revue De Pneumologie Clinique, 59(5 I), 333-335.
  • Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, Lomax L, Ashcroft L, Thatcher N & Middleton MR (2003) . J Clin Oncol, 21(13), 2551-2557.
  • Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R , Dowd I et al (2003) . Cancer, 98(3), 542-553.
  • Clamp A, Danson S & Clemons M (2003) . Surgeon, 1(1), 23-31.
  • Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S , Cosford R et al (2002) . J Clin Pharmacol, 42(7), 774-781.
  • Clamp A, Danson S & Clemons M (2002) . Lancet Oncol, 3(10), 611-619.
  • Clemons M, Danson S & Howell A (2002) . Cancer Treat Rev, 28(4), 165-180.
  • Danson SJ & Middleton MR (2001) . Expert Rev Anticancer Ther, 1(1), 13-19.
  • Clemons M, Danson S, Hamilton T & Goss P (2001) . Cancer Treat Rev, 27(2), 67-82.
  • Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN , Veal GJ et al () . British Journal of Cancer.
  • Geva R, Lopez JS, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Pereira KMC & Perets R () . European Journal of Nuclear Medicine and Molecular Imaging.

Book chapters

  • Danson SJ (2010) Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
  • Danson S, Teare MD & Woll P (2008) (pp. 183-192). Wiley
  • Danson SJ, Teare MD & Woll PJ (2008) Hereditary Tumours- From Genes to Clinical Consequences, Lung Tumours Wiley-VCH
  • Danson SJ (2007) Targeted therapy in non-small cell lung cancer, Non-Small Cell Lung Cancer Therapy UniMedScience
  • Danson SJ, Blackhall F, Baka S & Ranson M (2006) Novel therapies for mesothelioma, Malignant Pleural Mesothelioma Oxford University Press
  • Ranson M & Danson S (2003) Novel targeted approaches to the management of non-small cell lung cancer, Advances in Effective Management of Lung Cancer Aesculopius Medical Press

Conference proceedings

  • Mayland CR, Collinson M, Ahmedzai S, Lucas J, Gath J, Darlison L, Defonseka D, Laird B, Stanley H, Gardiner C , Danson S et al (2024) . ‘The (Richard) Light Fantastic’ – Pleural disease diagnosis and outcomes (pp A236-A237)
  • Shaw HM, Patel PM, Payne M, Kumar S, Danson S, Highley M, Prasad K, Board R, Barlow C, Larkin J , Young K et al (2024) A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab plus ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial. JOURNAL OF CLINICAL ONCOLOGY, Vol. 42(16)
  • Middleton G, Fletcher P, Savage J, Mehmi M, Greystoke A, Dangoor A, Cave J, Escriu C, Shaw P, Steele N , Jain P et al (2023) . Journal of Thoracic Oncology, Vol. 18(11) (pp S119-S120)
  • Shaw H, Patel P, Payne M, Kumar S, Danson S, Highley M, Barlow C, Miller R, Master F & Durrant L (2023) . Late-Breaking Abstracts (pp A1756-A1756)
  • Middleton G, Marshall L, Billingham L, Duffus KD, Greystoke A, Carter L, Forster MD, Cook N, Hargrave D, Danson S , Roxburgh P et al (2023) . Annals of Oncology, Vol. 34 (pp S494-S495)
  • Rahman MM, Wells G, Rantala J, Helleday T, Muthana M & Danson S (2023) . Annals of Oncology, Vol. 34 (pp S1177-S1177)
  • Shum B, Lobon I, Lesluyes T, Pallikonda H, Khoja LT, Kissoonsingh P, Nahm SH, El Badri S, Peleva E, Fusi A , Gault AC et al (2023) . Annals of Oncology, Vol. 34 (pp S1151-S1152)
  • Gupta A, Matin RN, Dayimu A, Nobes J, Board RE, Payne M, Rao AR, Fusi A, Danson S, Eccles BK , Carser J et al (2023) . Annals of Oncology, Vol. 34 (pp S669-S670)
  • Gagg H, Williams S, Rominiyi O, Danson S, Collis S & Wells G (2023) . Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
  • Ottensmeier CHH, Pinato DJJ, Armstrong AC, Symeonides SN, Patel PM, Danson S, Korolewicz J, Cameron D, Miller RM, Master F , Paston S et al (2023) Modi-1, anti-citrullinated neoepitope vaccine, alone and combined with checkpoint inhibitors in patients with head and neck, breast, renal, and ovarian cancers: ModiFy phase I/II basket clinical trial-Report after completion of monotherapy dose-finding. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
  • Griffiths GO, Griffiths D, Eminton Z, Hill K, Poile C, Nye M, Cave J, Danson S, Toy E, Jain P , Steele N et al (2023) A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
  • Guo C, Crabb SJ, Pacey S, Coyle V, Danson S, Villacampa G, Chandran K, Paschalis A, Riisnaes R, Ferreira A , Carreira S et al (2023) A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
  • Fennell DA, Ewings S, Hill K, Poile C, Baitei E, Zhou Z, Harber J, Kamata T, Yang H, Dzialo J , Faulkner D et al (2023) Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 41(16)
  • Middleton G, Fletcher P, Savage J, Mehmi M, Greystoke A, Dangoor A, Cave J, Escriu C, Shaw P, Steele N , Jain P et al (2023) A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S119-S120)
  • Lefley D, Jones C, Danson S, Bryant H, Collis S, Brown J & Ottewell P (2023) Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
  • Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) . Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022.
  • Fennell D, Ottensmeier C, Califano R, Hanna G, Ewings S, Hill K, Wilding S, Danson S, Nye M, Steele N , Johnson L et al (2021) Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(3) (pp S62-S62)
  • Mitchell T, Jones T, Danson S, Glover M, Bury J, Horsman J, Christian L, Hill E, Harrison E, Hatton M & Bryant H (2021) Investigation of Aurora Kinase A as a Potential Biomarker of Radiation in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S1163-S1164)
  • Mitchell T, Astley J, Robinson S, Bryant H, Danson S, Tahir B & Hatton M (2021) Artificial Neural Network-Based Tumour Recurrence Prediction in Non-Small Cell Lung Cancer Patients Following Radical Radiotherapy. JOURNAL OF THORACIC ONCOLOGY, Vol. 16(10) (pp S958-S958)
  • Danson SJ, Conner J, Edwards JG, Blyth KG, Fisher PM, Muthana M, Salawu A, Taylor F, Hodgkinson E, Joyce P , Roman J et al (2020) . Lung Cancer, Vol. 150 (pp 145-151)
  • Crabb SJ, Huddart RA, Brown E, Dunkley D, Downs N, McDowell C, Catto JWF, Griffiths GO, Danson S & Reid AH (2020) Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCG) in platinum refractory germ cell tumors (GCTs).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
  • Fennell DA, Lester JF, Danson S, Blackhall FH, Nicolson M, Nixon LS, Porter C, Gardner GM, White A, Griffiths GO & Casbard AC (2020) A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
  • Nathan P, Needham A, Corrie PG, Danson S, Evans J, Ochsenreither S, Kumar S, Goodman A, Larkin JMG, Karydis I , Steven NM et al (2019) SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM). ANNALS OF ONCOLOGY, Vol. 30
  • Elmushraf R, Clinch H, Salawu A, Fisher P, Young R, Lee C, Danson S, Bates E, Hatton M, Low L , Das T et al (2019) . Lung Cancer, Vol. 127 (pp S43-S43)
  • Danson S, Plummer R, Ottensmeier C, Hook J, Marshall H, Sagoo G, Meads D, Bestall J, Velikova G, Gallagher F , Smith A et al (2019) A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. BRITISH JOURNAL OF CANCER, Vol. 121 (pp 23-23)
  • Bird J, Nolan M & Danson SJ (2018) . Annals of Oncology, Vol. 29(suppl_8) (pp viii688-viii688). Munich, Germany, 19 October 2018 - 19 October 2018.
  • Peters S, Danson SJ, Hasan B, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D , Falchero L et al (2018) . Annals of Oncology, Vol. 29 (pp viii498-viii498)
  • Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) . Annals of Oncology, Vol. 29 (pp viii139-viii139)
  • Fennell D, Danson S, Forster M, Talbot D, Woll P, Child J, Ngai Y, Farrelly L, Hackshaw A, Sharkey A , Busacca S et al (2018) . Journal of Thoracic Oncology, Vol. 13(10) (pp S397-S397)
  • Fennell DA, Kirkpatrick EV, Cozens K, Danson S, Hanna GG, Lester JF, Lord J, Nye M, Ottensmeier CHH, Szlosarek PW , Steele NL et al (2018) . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS8586-TPS8586)
  • Crabb SJ, Danson S, Catto J, McDowell C, Dunkley D, Huddart RA & Griffiths G (2018) . Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594)
  • Wells G, Kohlmann A, Ratcliffe M, Wilson G, Dalton A & Danson S (2018) . European Journal of Surgical Oncology, Vol. 44 (pp S36-S36)
  • Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2018) . European Journal of Surgical Oncology, Vol. 44 (pp S26-S27)
  • Danson SJ, Perets R, Lopez J, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger B, Pereira KMC & Geva R (2018) . Cancer Research, Vol. 78(4_Supplement)
  • Garikipati S, Prakash A, Alhilali M, Burnett A, Lee C, Young R, Danson S, Bates E, Fisher PM, Hatton MQ & Das T (2018) . Lung Cancer, Vol. 115 (pp S73-S73). Dublin , 24 January 2018 - 24 January 2018.
  • Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29
  • Low L, Salawu A, Bates E, Young R, Danson S, Fisher PM, Hatton MQ, Lee C, Das T & Taylor F (2018) . Lung Cancer, Vol. 115 (pp S35-S35). Dublin, Ireland, 24 January 2018 - 24 January 2018.
  • Hanna G, Griffiths G, Kirkpatrick EV, Cozens K, Kalevras M, Maishman T, Danson S, Lester J, Ottensmeier C, Steele N , Szlosarek P et al (2018) . Lung Cancer, Vol. 115(Suppl 1) (pp S84-S84). Dublin, 24 January 2018 - 24 January 2018.
  • Fennell D, Kirkpatrick E, Cozens K, Danson S, Hanna G, Lester J, Lord J, Nye M, Ottensmeier C, Szlosarek P , Steele N et al (2017) . Journal of Thoracic Oncology, Vol. 12(11) (pp S2376-S2376)
  • Wells G, Kohlmann A, Ratcliffe M, Wilson G, Dalton A & Danson S (2017) . European Journal of Surgical Oncology, Vol. 43(11) (pp 2233-2233)
  • Silva S, Cox A, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Parker M, Cramp H & Danson S (2017) . European Journal of Surgical Oncology, Vol. 43(11) (pp 2225-2225)
  • Valicenti RK, Perets R, Lopez J, Danson S, Joensuu HT, Peer A, Harris SJ, Souza F, Ploeger B, Pereira KMC & Geva R (2017) . International Journal of Radiation Oncology*Biology*Physics, Vol. 99(2) (pp E269-E269)
  • Danson S, Woll P, Edwards J, Blyth K, Fisher P, Roman J, Simpson K, Spavin R, Learmonth K & Conner J (2017) . Annals of Oncology, Vol. 28 (pp v122-v122)
  • Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger BA, Pereira KMC & Perets R (2017) . Annals of Oncology, Vol. 28 (pp v138-v138)
  • Middleton MR, Schadendorf D, Danson S, Marshall E, Corrie P, Love SB, Mohammed SB, Scudder C & Goff M (2017) . Cancer Research, Vol. 77(13_Supplement) (pp CT123-CT123)
  • Hiley CT, Ahmad T, Jamal-Hanjani M, Abbosh C, Ngai Y, Hackshaw A, Patterson P, Baijal S, Nicolson M, Lester JF , Krebs M et al (2017) . Journal of Clinical Oncology, Vol. 35(15_suppl) (pp TPS9099-TPS9099)
  • Marshall R, Kakoudaki M, Danson SJ, Fisher PM, Hatton MQ, Lee CE, Das T, Bates E, Woll P & Taylor F (2017) . Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 25 January 2017.
  • Kakoudaki M, Marshall R, Danson SJ, Fisher PM, Hatton MQ, Lee CE, Das T, Bates E, Woll P & Taylor F (2017) . Lung Cancer, Vol. 103(Suppl 1) (pp S31-S31). Dublin, Ireland, 25 January 2017 - 25 January 2017.
  • Adams E, Cheng C-Y, Sacco J, Danson S, Corrie P, Nathan P, Szlosarek P, Upton J, Amuludun A & Toward T (2017) Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. JOURNAL FOR IMMUNOTHERAPY OF CANCER, Vol. 5
  • Woll P, Gaunt P, Steele N, Ahmed S, Mulatero C, Shah R, Danson S, Hodgkinson E, James K, Watkins B , Fletcher P et al (2017) . Journal of Thoracic Oncology, Vol. 12(1) (pp S704-S705)
  • Geva R, Lopez J, Danson S, Joensuu H, Peer A, Harris SJ, Souza F, Ploeger BA, Pereira KMC & Perets R (2017) An open-label, multicenter Phase 1b study of radium-223+paclitaxel in cancer patients with bone metastases. ANNALS OF ONCOLOGY, Vol. 28
  • Silva S, Teare D, Bradford J, Brock I, Connley D, Jarratt E, Cramp H, Taylor F, Cox A & Danson S (2016) . European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S245-S245)
  • Wilshaw V, Das T, Hatton N, Fisher PM, Lee CE, Danson SJ, Woll PJ & Hatton MQ (2015) . Lung Cancer, Vol. 87 (pp S33-S33)
  • Taylor F, Viggars A, Daniels S, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2015) . Lung Cancer, Vol. 87 (pp S20-S20)
  • Corrie P, Marshall A, Dunn J, Middleton MR, Nathan PD, Gore ME, Davidson D, Nicholson S, Kelly CG, Marples M , Danson S et al (2014) . Lancet Oncology, Vol. 15(6) (pp 620-630)
  • Thomas SJ, Fisher K, Brown S, Snowden JA, Danson S & Zeidler M (2014) . Blood, Vol. 124(21) (pp 4577-4577)
  • Danson S, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz S , Kaye JA et al (2014) . Annals of Oncology, Vol. 25 (pp iv415-iv415)
  • Ottensmeier C, Galea I, Cross N, Maishman T, Hamid D, Cave J, Wheater M, Geldart T, Mulatero C, Potter V , Danson S et al (2014) . Annals of Oncology, Vol. 25 (pp iv516-iv516)
  • Silva S, Colquitt J, Hatton MQ, Mohanamurali J, Lee C, Danson S, Fisher P & Woll P (2014) . LUNG CANCER, Vol. 83 (pp S13-S13)
  • Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan P et al (2013) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.. Journal of Clinical Oncology, Vol. 31
  • Corrie P, Marshall A, Goonewardena M, Dunn JA, Middleton MR, Nathan PD, Gore ME, Davidson N, Nicholson S, Kelly CG , Marples M et al (2013) AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, Vol. 31
  • Ahmad S, Qian W, Ellis SG, Khattak MA, Thillai K, Board RE, Nobes J, Dalgleish A, Grummet SA, Maraveyas A , Danson S et al (2013) Ipilimumab in the real world: the UK expanded access programme (EAP) experience in metastatic melanoma. Journal of Clinical Oncology, Vol. 31
  • Talbot DC, Blackhall FH, Kowalski D, Ramlau R, Belper G, Grossi F, Lerchenmuller CA, Pinder MC, Mczger J, Danson S , Callies S et al (2013) A randomized open-label phase II study evaluating antitumor activity of the survivin antisense oligonucleotide LY2181308 (LY) in combination with docetaxel (DO) for second-line treatment of patients with non-small cell lung cancer (NSCLC) using change in tumor size (CTS).. Journal of Clinical Oncology, Vol. 31
  • Sacco J, Nathan P, Danson S, Lorigan P, Nicholson S, Ottensmeier C, Corrie P, Steven N, Larkin J, Goodman A , Evans J et al (2013) Sunitinib versus dacarbazine as first line treatment in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, Vol. 31
  • Corrie P, Marshall A, Goonewardena M, Dunn JA, Middleton MR, Nathan PD, Gore ME, Davidson N, Nicholson S, Kelly CG , Marples M et al (2013) Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(18)
  • Gupta A, Love S, Schuh A, Collins L, Thomason A, Asher R, Lisle R, Churchman M, Shanyinde M, Plummer R , Nathan PD et al (2013) DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Woll P, Danson S, Edwards J, Goldsborough S, Fisher P & Conner J (2013) ONCOLYTIC HERPES VIRUS THERAPY FOR MESOTHELIOMA- A PHASE I STUDY OF INTRAPLEURAL ONCOLYTIC VIRUS HSV1716 (NCT01721018). JOURNAL OF THORACIC ONCOLOGY, Vol. 8 (pp S940-S941)
  • Bowen K, Walkington L, Evans LS & Danson SJ (2013) . LUNG CANCER, Vol. 79 (pp S14-S14)
  • Woll PJ, Danson SJ, Edwards JG, Fisher PM & Conner J (2013) . LUNG CANCER, Vol. 79 (pp S34-S34)
  • Best J, Young R, Ddamba J, Danson SJ, Fisher PM, Foran B, Hatton M, Lee C, Mohanamurali J & Woll PJ (2013) . LUNG CANCER, Vol. 79 (pp S15-S16)
  • Khan F, Ottensmeier C, Popat S & Danson SJ (2013) . LUNG CANCER, Vol. 79 (pp S10-S11)
  • Nugent L, Das T, Mohanamurali J, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2013) . LUNG CANCER, Vol. 79 (pp S9-S9)
  • Stansfield R, Mohanamurali J, Danson SJ, Fisher PM, Hatton MQ, Lee CE & Woll PJ (2013) . LUNG CANCER, Vol. 79 (pp S15-S15)
  • Shaw H, Larkin J, Corrie P, Ellis S, Nobes J, Marshall E, Kumar S, Danson S, Plummer R & Nathan P (2012) IPILIMUMAB FOR ADVANCED MELANOMA IN AN EXPANDED ACCESS PROGRAMME (EAP): OCULAR, MUCOSAL AND ACRAL SUBTYPE UK EXPERIENCE. ANNALS OF ONCOLOGY, Vol. 23 (pp 374-374)
  • Danson S, Rowland C, Eiser C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton M & Woll P (2012) Implications of smoking for quality of life and illness perceptions of lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Marshall E, Coupland S, Corrie P, Damato B, Danson S, Dobson L, Evans TRJ, Goodman A, Kalirai H, Jones S , Kumar S et al (2012) A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • O'Brien M, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier CHH, Danson S, Pallis AG , Hasan B et al (2012) Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
  • Rowland C, Eiser C, Rowe R & Danson S (2012) Exploring quality of life of lung cancer patients and their partners by smoking history. PSYCHOLOGY & HEALTH, Vol. 27 (pp 110-110)
  • Rowland C, Eiser C, Rowe R & Danson S (2012) . LUNG CANCER, Vol. 75 (pp S44-S45)
  • Das TS, Hatton NFL, Danson S, Fisher PM, Lee C, Mohanamurali J, Woll PJ & Hatton MQF (2012) . LUNG CANCER, Vol. 75 (pp S10-S10)
  • Quinn AM, Blackhall F, Danson S, Wilson G, Brierley J, White E, Keeling C, Clamp A, Ashcroft L & Hasleton PS (2011) Extrapulmonary Small Cell Carcinoma: A Clinicopathological Study with Identification of Diagnostic Mimics. JOURNAL OF PATHOLOGY, Vol. 224 (pp S15-S15)
  • Das T, Durkie M, Woll PJ, Hatton MQ, Mohanamurali J, Lee C, Fisher PM & Danson S (2011) Testing for epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based analysis in North Trent. LUNG CANCER, Vol. 71 (pp S13-S13)
  • Alzouebi M, Fisher P, Woll PJ, Hatton MQ, Foran B, Mohanamurali J & Danson S (2010) Audit of adjuvant vinorelbine and cisplatin for patients with resected NSCLC. LUNG CANCER, Vol. 67 (pp S3-S3)
  • Wheatley-Price P, Blackball F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian WD, Hackshaw A, Rudd R, Booton R , Danson S et al (2009) The influence of sex and histology on outcomes in non-small cell lung cancer: a pooled analysis of 5 randomized trials. J THORAC ONCOL, Vol. 4(9) (pp S286-S287)
  • Woll PJ, Edwards JG, Danson S, Fisher PM, Matthews S & Conner J (2009) Oncolytic virus therapy for mesothelioma - a phase I trial proposal. LUNG CANCER, Vol. 63 (pp S26-S27)
  • Danson S, Shaw K, Bruce L, Wadsley J, Fisher P, Foran B, Mohanamurali J, Trigg M, Joyce P, Woll PJ & Hatton MQ (2007) Outreach chemotherapy: convenience versus quality?. LUNG CANCER, Vol. 57 (pp S5-S5)
  • Danson S, Johnson P, Ward T, Dawson M, Deneny O, Watson A, Jowle D, Sharpe P, Dive C & Ranson M (2007) Final results of a phase I clinical trial of the bioreductive drug RH1. Journal of Clinical Oncology, Vol. 25
  • Danson S, Johnson P, Ward T, Dawson M, Denneny O, Cummings J, Jowle D, Howard E, Dive C & Ranson M (2005) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the bioreductive drug RH1.. CLINICAL CANCER RESEARCH, Vol. 11(24) (pp 9150S-9150S)
  • Danson S, Clamp A, Davidson S, Wylie J, Ashcroft L, Wardley A, Anderson H, Hasleton P & Thatcher N (2005) Extrapulmonary small cell carcinoma: Our experience over ten years. LUNG CANCER, Vol. 49 (pp S317-S317)
  • O'Byrne K, Clarke L, Dunlop D, Ranson M, Danson S, Botwood N & Carbone D (2004) Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 22(14) (pp 641S-641S)
  • Ward TH, Danson S, Dawson M, McGrath H, Denneny O, Cummings J, Dive C & Ranson M (2004) Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.. BRITISH JOURNAL OF CANCER, Vol. 91 (pp S60-S60)
  • Wardley A, Danson S, Clayton A, Clemons M, Waine S, Burt P, Stewart A, Wilkinson P, Welch R, Magee B & Howell A (2002) High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer centre. Journal of Clinical Oncology
  • Danson S, Arance A, Lorigan P, Clamp A, Hodgetts J, Lomax L, Ashcroft L & Thatcher N (2002) A randomized study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Journal of Clinical Oncology
  • Lorigan P, Danson S, Clamp A, Hodgetts J, Lomax L, Ashcroft L, Middleton MR & Thatcher N (2002) Toxicity of temozolomide with response modifiers in metastatic malignant melanoma. BRIT J CANCER, Vol. 86 (pp S68-S68)
  • Danson S, Clemons M, Middleton MR, O'Bryne K, Hassan J, Anderson H, Burt P, Stout R, Swindell R, Dowd I , Beresford C et al (2001) A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
  • Valle JW, Danson S, Burgess A, Meehan M & Hawkins RE (2001) The use of sandostatin-LAR in the treatment of carcinoid syndrome - experience from a single centre. Journal of Clinical Oncology
  • Danson S, Clemons M, Middleton MR, O'Bryne K, Hassan J, Anderson H, Burt P, Stout R, Swindell R, Dowd I , Beresford C et al (2001) A randomised study of gemcitabine with carboplatin (GC) versus mitomycin C, vinblastine and cisplatin (MVP) or mitomycin C, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer. Journal of Clinical Oncology
  • Danson SJ, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz S , Kaye JA et al () . Annals of Oncology(25 (supp 4)) (pp iv 409-iv 416). Madrid, 26 September 2014 - 30 September 2014.

Reports

  • Danson S (2009) Second line chemotherapy for small cell lung cancer

Other

  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y , Hackshaw A et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
  • Crabb SJ, Danson S, Catto JWF, Hussain S, Chan D, Dunkley D, Downs N, Marwood E, Day L, Saunders G , Light M et al (2023) .
Research group

Ex Vivo group (Clinical Lead)

  • Dr Greg Wells
  • Dr Juha Rantala (Honorary post)
  • Dr Spencer Collis
  • Professor Jim Catto
  • Mr Ola Rominyi
  • Dr Robin Young
  • Dr Alberto Biancardi
  • Dr Jamie Adams

PhD students

  • Dr Shobha Silva
  • Dr Tim Mitchell
  • Dr Amy Kwan
  • Dr Marufur Rahman
  • Dr Sonal Hapuarachi
  • Morgan Rycroft
Teaching interests

My undergraduate teaching involves one to one teaching in clinic and on the ward and lecturing on the MSC in Translational Oncology course. Postgraduate interests include teaching to all grades of doctor in a wide variety of fields such as oncology (on the systemic cancer chemotherapy course), dermatology, plastic surgery and respiratory medicine.

Professional activities and memberships

Professional roles

  • Director of Research, School of Medicine and Population Health.
  • Co-Clinical Lead for the National Cancer Vaccine Programme.
  • Sheffield Early Phase Oncology Lead.
  • Past Chair of the UK ECMC Strategy Group.
  • Co-lead for the ‘Improving Outcomes’ Theme of the University Oncology Strategy.
  • NIHR National Speciality Lead for Cancer: Early Phase Trials.

I am a member of:

  • Member of the NCRI Conference Organising Committee.
  • EORTC Melanoma Group.
  • EORTC Lung Group.